PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Acamprosate→

Acamprosate PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
77337-76-9
Molecular formula
C5H11NO4S
Molecular weight
181.21 g/mol
Drug class
Glutamatergic/GABAergic neuromodulatorsynthetic taurine analogue used in alcohol-dependence relapse prevention
Mechanism of action
The exact mechanism by which acamprosate supports maintenance of abstinence is not fully understood. Experimental data suggest modulation of glutamatergic (particularly NMDA-related) and GABAergic neurotransmission during alcohol withdrawal-related neuroadaptation; these pathways should be presented as proposed rather than confirmed clinical targets.
Indications / reported uses
  • Maintenance of alcohol abstinence in adults with alcohol dependence who are abstinent when treatment is initiated; use as part of a comprehensive psychosocial treatment programme. It does not treat acute alcohol withdrawal.

Sources: US DailyMed — Acamprosate calcium prescribing information · UK SmPC — Acamprosate 333 mg gastro-resistant tablets · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Acamprosate PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Acamprosate Permitted Daily Exposure (PDE) report (the Acamprosate PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Acamprosate Occupational Exposure Limit (OEL) report (the Acamprosate OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.